http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2193201-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23ddfc3967071f88e7923f184654a621 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2001-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeb0f4590a37207ced5ac53d44f22e6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b508e23ad32a79bfebeacf7903a0741d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80436a3dcdd0c939e88ed1d97b32a46f |
| publicationDate | 2002-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2193201-C1 |
| titleOfInvention | Method for predicting development of lingering forms of yersiniosis infection in children |
| abstract | FIELD: medicine. SUBSTANCE: one should determine the phenotype of blood mononuclear cells with the help of vast panel of monoclonal antibodies, immunoglobulin E and blood serum gamma-interferon. Moreover, at acute phase one should estimate CD8+, CD20+, CD25+, CD95+ cells, immunoglobulin E and blood serum gamma-interferon and according to the content of CD8+ cells being below 17.7%; CD25+ cells, below 17%; CD95+ cells, below 26%; CD20+ cells, above 36%; immunoglobulin E level, above 600 kU/l; gamma-interferon level, below 40 pg/ml one should predict the development of lingering yersiniosis infection flow in children. EFFECT: higher accuracy of prediction. 3 ex, 3 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2568904-C1 |
| priorityDate | 2001-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.